CJC-1295 with DAC | Peptide Reference Material
RESEARCH PEPTIDE

CJC-1295 with DAC | Peptide Reference Material

Synthetic GHRH Analog with DAC — Research Peptide
$79.00
CJC-1295 with DAC laboratory peptide reference material. CAS and conjugate identity remain under scientific review. Research use only; not for human or veterinary use.
✓ Identity Verified
✓ Batch Documentation
✓ QR Lot Verification
✓ Research Use Only
✓ U.S. Fulfillment
✓ Batch Verification Available View verification →
Lot Verification Variant-specific documentation
Traceable Lots VBL lot identification
Primary Literature Peer-reviewed sources
Research Use Only Laboratory research materials

Scientific Specifications

Reference characteristics for laboratory research materials.

CAS Number
446262-90-4
Purity
≥98%
Molecular Formula
C165H269N47O46
Molecular Weight
3647.28
Appearance
White lyophilized powder
Storage
-20°C
Research Classification
Research Use Only (RUO). Not for human or veterinary use.

SCIENTIFIC OVERVIEW

Scientific background and research classification for this laboratory reference material.

This catalog material is labeled CJC-1295 with DAC. Supplied records conflict on CAS identity; no disputed CAS, formula, molecular mass, sequence, or conjugate-form value is adopted here. Research use only.

Primary Research Category
Growth Hormone Research
Material Type
Lyophilized Peptide
Intended Use
Laboratory Research
Research Categories
Growth Hormone Axis Endocrine Research Receptor Pharmacology Hormonal Regulation

Mechanism of Action

Molecular interaction profile describing how this research material engages receptor systems and influences downstream biological signaling pathways.

No product-specific receptor, albumin-binding, or pharmacokinetic claim is assigned until the exact DAC conjugate identity is independently resolved.

Primary Organ Systems
  • Endocrine System

Research Documentation

Laboratory documentation is presented when available for the selected product specification and current lot.

Batch Verified
Independent Batch Verification

Independent laboratory verification for this batch:

  • Identity Confirmation
  • HPLC Purity Analysis
  • Net Peptide Content
  • Endotoxin Testing
  • Analytical Chromatogram
  • Independent Laboratory Verification
View Batch Verification →
Scientific References
Peer-Reviewed Literature

Explore published literature, clinical investigations, and foundational scientific research.

View References →
Laboratory Resources
Technical Guidance

Storage guidance, handling recommendations, analytical methods, and laboratory best practices.

Related Research
Companion Materials

Discover complementary research materials frequently studied alongside this compound.

Research Center

Scientific literature, laboratory resources, and related materials curated to support research involving this research material.

Scientific References
Peer-Reviewed Literature

Explore curated publications from peer-reviewed journals including clinical investigations, mechanistic studies, and foundational scientific literature.

Browse References →
Scientific Dossier
Deeper Technical Treatment

Comprehensive scientific documentation including literature review, mechanism, pharmacology, and study data for this research material.

Laboratory Resources
Technical Guidance

Storage guidance, handling information, analytical standards, research policies, and laboratory support documentation.

Research Library

Curated peer-reviewed literature selected to provide scientific context for this research material.

Mechanistic Study•Endocrinology• 2005

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog

Foundational study showing that hGRF(1-29)-albumin bioconjugates (the DAC technology) activate the GRF receptor on the rat anterior pituitary and identifying CJC-1295 as a long-lasting GRF analog — the mechanistic and identity origin of the DAC form.
Velora Research Insight
Establishes the DAC/albumin-bioconjugate mechanism and the GRF-receptor (GHRH-receptor) site of action — the basis for the reported molecular-target vocabulary gap (GRF receptor not governed). ConjuChem originating development lineage (Bridon et al.).
PubMed →DOI →
Clinical Trial•The Journal of Clinical Endocrinology and Metabolism• 2006

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Early-clinical study in healthy adults reporting that CJC-1295 produced prolonged stimulation of growth-hormone and IGF-1 secretion — human pharmacology of the GHRH analog, recorded as scientific context at its evidence level.
Velora Research Insight
Human pharmacology (early-clinical) of the GHRH analog. Carried strictly as evidence-scoped scientific context, NOT as a product efficacy/performance claim. Frohman + ConjuChem (Castaigne) development lineage.
PubMed →DOI →
Clinical Trial•The Journal of Clinical Endocrinology and Metabolism• 2006

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

Early-clinical study reporting that pulsatile GH secretion persists during continuous stimulation by CJC-1295, characterizing the pattern of GH release under the long-acting GHRH analog.
Velora Research Insight
Complementary early-clinical GH-secretion-dynamics finding. Frohman lineage (shared with VSE-PUB-000101) — investigator concentration disclosed; not an additional independent lineage. Scientific context only.
PubMed →DOI →
Review Article•Frontiers in Endocrinology• 2026

The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis: bridging the gap between science and misuse

Recent independent review of peptides modulating the GH-IGF1 axis, including GHRH analogs such as CJC-1295, synthesizing the evidence and explicitly addressing the gap between the science and non-approved/performance misuse.
Velora Research Insight
Fully independent recent synthesis (no ConjuChem/Frohman overlap). Contextualizes CJC-1295 within the GH-IGF1 axis and explicitly flags misuse — the key claims-safety anchor; reinforces RUO framing and the non-endorsement of performance use.
PubMed →DOI →